Post

New research · Ophthalmology
Clinical ophthalmology (Auckland, N.Z.) · 14h
Cohort studyClinical ophthalmology (Auckland, N.Z.) · 2026

One-Year Outcome of PreserFlo MicroShunt Implantation in Patients with Open Angle Glaucoma: Real-World Data from a Tertiary Centre.

Teck Chee Cheng, Khai Voon Ng, Jemaima Che Hamzah
Read paper
OphthalmologyCohort study

PreserFlo MicroShunt was linked to lower intraocular pressure one year after surgery for open angle glaucoma.

One-Year Outcome of PreserFlo MicroShunt Implantation in Patients with Open Angle Glaucoma: Real-World Data from a Tertiary Centre.

Teck Chee Cheng … Jemaima Che Hamzah
Clinical ophthalmology (Auckland, N.Z.) · 2026
Purpose

To evaluate the one-year clinical outcomes, safety profile, and surgical success of the PreserFlo ® MicroShunt in patients with glaucoma treated at a tertiary referral centre in Malaysia.

Methods

This retrospective study included 40 eyes of 31 patients undergoing PreserFlo MicroShunt implantation performed by two experienced surgeons using a standard ab-externo technique with mitomycin C (0.04% for 3 minutes) and a structured postoperative corticosteroid tapering regimen.

n = 40 eyes
Results

average eye pressure checked one year after surgery, much lower than before

3.8
Before
0.2
After
More results

The median number of glaucoma medications decreased from 3.8 to 0.2 drops.

At one-year, complete surgical success was achieved in 82.5% of eyes, while qualified success was 95.0%.

Surgical failure occurred in 5.0% of eyes.

More results

Early postoperative hypotony (IOP ≤5 mmHg) occurred in 17.5%, with persistent hypotony at one year in 2.5%, none of which resulted in vision loss.

“
Conclusion · 1 of 3

PreserFlo MicroShunt implantation was associated with reductions in IOP and glaucoma medication burden at one year, with generally acceptable short-term safety outcomes.

Conclusion · 2 of 3

These findings support its role as an effective bleb-forming minimally invasive glaucoma surgery option for patients requiring lower target IOPs, including those with advanced glaucoma.

Conclusion · 3 of 3

However, the results should be interpreted in the context of the modest sample size, retrospective design, absence of a comparator group, and need for postoperative interventions.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment